Survival of primary, but not of cancer cells after combined Plk1-HDAC inhibition

Lisa Lange; Peter Hemmerich; Birgit Spänkuch

doi:10.18632/oncotarget.4445

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Survival of primary, but not of cancer cells after combined Plk1-HDAC inhibition

Lisa Lange, Peter Hemmerich and Birgit Spänkuch _

PDF | HTML | How to cite

Oncotarget. 2015; 6:25801-25814. https://doi.org/10.18632/oncotarget.4445

Metrics: PDF 1650 views | HTML 2224 views | ?

Abstract

Lisa Lange1, Peter Hemmerich2, Birgit Spänkuch1

1Friedrich-Schiller-University, CMB, Institute for Biochemistry and Biophysics, 07745 Jena, Germany

2Leibniz-Institute for Age Research-Fritz Lipmann Institute, JenAge (Jena Centre for Systems Biology of Aging), 07745 Jena, Germany

Correspondence to:

Birgit Spänkuch, e-mail: [email protected]

Keywords: polo-like kinase 1, HDAC, p21, cell cycle, cancer

Abbreviations: Plk1 - polo-like kinase 1; HDAC - histone deacetylase; HDACi - histone deacetylase inhibitor; SAHA - suberoylanilide hydroxamic acid; pRb - phospho-Rb

Received: February 24, 2015 Accepted: June 16, 2015 Published: June 26, 2015

ABSTRACT

In the current study we examined the combination of SAHA and SBE13 in cancer and non-cancer cells. HeLa cells displayed a synergistically reduced cell proliferation, which was much weaker in hTERT-RPE1 or NIH-3T3 cells. Cell cycle distribution differed in HeLa, hTERT-RPE1 and NIH-3T3 cells. SAHA-treated HeLa cells showed slightly increasing cell numbers in G2/M phase, but after combination with SBE13 strongly elevated cell numbers in G2/M and S phase, accompanied by decreasing G0/G1 percentages. hTERT-RPE1 and NIH-3T3 cells showed strongly enriched cell numbers in G0/G1 phase. Western blot and quantitative real time analyses revealed reduced Plk1 mRNA and protein in all cells. p21 protein was strongly induced in cancer, but not in non-cancer cells, corresponding to a different localization in immunofluorescence studies. Additionally, these revealed an abundantly present pRb protein in HeLa cells after any treatment but almost completely vanished pRb staining in treated hTERT-RPE1 cells. These differences could be approved in Western blots against Parp and Caspase 3, which were activated in HeLa, but not in hTERT-RPE1 cells. Thus, we observed for the first time a differential effect of cancer versus non-cancer cells after treatment with SAHA and SBE13, which might be due to the dual role of p21.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 4445

Publication Alerts

Research Papers:

Survival of primary, but not of cancer cells after combined Plk1-HDAC inhibition

Abstract